A Revolutionary Tech for Exceptionally Efficient Natural Muscle Tissue Growth in Cultivated Meat Applications
ProFuse aims to optimize a novel myoblast cell line and media supplement to enhance the scalability and quality of cultivated meat, targeting TRL6 validation with potential clients.
Projectdetails
Introduction
Whilst meat demand is expected to double by 2050, consumption needs to drop by 50% to reduce greenhouse gases and preserve land. Cultivated meat - meat products manufactured through the harvesting and proliferation of animal cells - offers a feasible alternative, supplying animal protein at minimal environmental costs.
Industry Challenges
However, the industry faces significant challenges linked to:
- Production costs
- Ability to scale-up
- Final product quality
The main technical bottlenecks arise from the need to continuously source cells from live animals, and inefficient differentiation and maturation processes that fail to achieve nutritional and organoleptic characteristics to satisfy consumers.
ProFuse Innovations
Harnessing unique expertise on muscle cultivation, ProFuse has developed:
- The first spontaneously immortalized and stable myoblast cell line (bovine) with remarkable proficiency in both muscle tissue proliferation and differentiation.
- A media supplement capable of driving the highly effective fusion and maturation into contractile muscle, successfully mimicking natural muscle development.
Development and Partnerships
After receiving the licensing of the patent protecting the discovery and the incorporation of our start-up for boosting development and commercialization, our team has established strong relationships with worldwide leading cultivated meat producers and suppliers. We are developing initial supplement formulations for different 2D and 3D applications.
Project Goals
Through this project, we aim at optimizing our combined cell-line + supplement solution for scale-up, enabling 3D production techniques. Our objectives include:
- Reaching validation in a relevant environment with at least 3 potential clients.
- Preparing the certification dossier.
Thus, we aim to bring our combined cell-line + supplement solution to TRL6.
Conclusion
ProFuse will transform the scale-up potential and quality of final cultivated meat products, fast forwarding the industry to high uptake scenarios.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.432.030 |
Totale projectbegroting | € 2.432.030 |
Tijdlijn
Startdatum | 1-4-2024 |
Einddatum | 31-3-2026 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- PROFUSE TECHNOLOGY LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Precommercializing a Method For Inducing Muscle Fiber Formation For Industrial Meat ProductionThis project aims to enhance in vitro muscle formation for cultured meat production by leveraging a novel signaling cascade to improve efficiency and commercialization potential. | ERC POC | € 150.000 | 2022 | Details |
Innovative patented dry fermentation technology for cost-effective and highly nutritious production of hybrid mycelium-plant meat analoguesThe MEATLOW project aims to optimize a novel mycelium-plant fermentation technology to produce healthy, eco-friendly meat analogues for the EU market by 2026. | EIC Accelerator | € 2.441.250 | 2024 | Details |
New Micro-extrusion Advanced Technology for plant-based whole-cut meat substitutesNOVAMEAT uses tissue engineering and 3D printing to create sustainable, plant-based whole-cut meat alternatives with diverse nutritional and sensory profiles, addressing overpopulation and climate issues. | EIC Accelerator | € 1.860.725 | 2022 | Details |
Using biotechnology to create the next generation of sustainable foods from the roots of mushroomsMushlabs uses proprietary fermentation technology to cultivate mycelium into a sustainable, protein-rich meat alternative, aiming to transform plant-based diets. | EIC Accelerator | € 2.426.375 | 2022 | Details |
Precommercializing a Method For Inducing Muscle Fiber Formation For Industrial Meat Production
This project aims to enhance in vitro muscle formation for cultured meat production by leveraging a novel signaling cascade to improve efficiency and commercialization potential.
Innovative patented dry fermentation technology for cost-effective and highly nutritious production of hybrid mycelium-plant meat analogues
The MEATLOW project aims to optimize a novel mycelium-plant fermentation technology to produce healthy, eco-friendly meat analogues for the EU market by 2026.
New Micro-extrusion Advanced Technology for plant-based whole-cut meat substitutes
NOVAMEAT uses tissue engineering and 3D printing to create sustainable, plant-based whole-cut meat alternatives with diverse nutritional and sensory profiles, addressing overpopulation and climate issues.
Using biotechnology to create the next generation of sustainable foods from the roots of mushrooms
Mushlabs uses proprietary fermentation technology to cultivate mycelium into a sustainable, protein-rich meat alternative, aiming to transform plant-based diets.